CHKA and Hypoglycemia: As described in Results, DS-4108b showed robust and long-term efficacy with regard to the various abnormalities in cKI-Mut mice, such as fasting hypoglycemia, hepatomegaly, and metabolic changes, suggesting a favorable therapeutic effect in a clinical context.